Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alemtuzumab + deoxyspergualin
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Alemtuzumab + deoxyspergualin is an experimental combination therapy consisting of two agents: - **Alemtuzumab** is a humanized monoclonal antibody targeting CD52, a glycoprotein present on the surface of mature lymphocytes. It induces profound depletion of T and B lymphocytes via antibody-dependent cellular cytolysis and complement-mediated lysis. Alemtuzumab is approved for the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis. - **Deoxyspergualin (DSG)** is an immunosuppressive agent with inhibitory effects on monocytes and macrophages. This combination has been studied in renal transplantation to test whether perioperative T-cell depletion with alemtuzumab plus short-course DSG could induce immune tolerance to allografts by suppressing both lymphocyte and monocyte/macrophage activity. In clinical trials, this regimen did not achieve tolerance but resulted in reversible rejection episodes similar to those seen with alemtuzumab alone[1].
- Brand names
- CampathLemtrada
- Other names
- Campath-1HCampath1HCampath 1H15-deoxyspergualin
02
Targets
CD52 (CD52 Antigen)
Beyond the preview
Go deeper on alemtuzumab + deoxyspergualin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alemtuzumab + deoxyspergualin.